stockrowAlkermes plc
ALKS Healthcare Drug Manufacturers Specialty & Generic
Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.
- Revenue
- +21.8%
- EPS
- −80.6%
- Free cash flow
- +6.78%
Quarter to September 2026, against a year earlier
Follow ALKS
Alert me
Alkermes plc (ALKS) Revenue
Alkermes plc's revenue for fiscal 2025 was $1.5B, down 5.25% from $1.6B in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.8B. Over the past ten years it has ranged from $628.3M (fiscal 2015) to $1.7B (fiscal 2023); the current reading is higher than 82% of that period. Alkermes plc ranks 14th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $1.5B | (5.25%) |
| FY2024 | $1.6B | (6.36%) |
| FY2023 | $1.7B | 49.61% |
| FY2022 | $1.1B | (5.28%) |
| FY2021 | $1.2B | 13.00% |
| FY2020 | $1.0B | (11.29%) |
| FY2019 | $1.2B | 7.01% |
| FY2018 | $1.1B | 21.13% |
| FY2017 | $903.4M | 21.15% |
| FY2016 | $745.7M | 18.68% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $480.1M | (3.20%) |
| Jun 2026 | $496.0M | 26.24% |
| Mar 2026 | $392.9M | 2.18% |
| Dec 2025 | $384.5M | (2.45%) |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ELAN Elanco Animal Health Incorporated compare | $5.0B |
| RDY Dr. Reddy's Laboratories Ltd compare | $3.3B |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $3.2B |
| HIMS Hims & Hers Health, Inc. compare | $2.6B |
| ALKS Alkermes plc | $1.8B |
| LNTH Lantheus Holdings, Inc. compare | $1.6B |
| SUPN Indivior Pharmaceuticals Inc. compare | $1.4B |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $946.0M |
| LQDA Liquidia Corporation compare | $450.9M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ALKS
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement